Shanghai Ayk Biotechnology Co., Ltd
It is a subsidiary of Chengdu Makkang Biology, which focuses on the research and development of new therapeutic tumor vaccines. It was founded by a number of returned doctors in chemical biology and well-known domestic experts. The company has rich experience in complex sugar chemistry and industrialization.
Industry leading
Senior management team
New product progress
Focusing on the research and development of new therapeutic tumor vaccines, an internationally leading new adjuvant platform.
Founded by overseas returnees and well-known domestic experts, it has more than 20 years of research experience in sugar chemical R&D industrialization.
PRODUCT  SERVICE
With more than 20 years of research experience in sugar chemistry R&D industrialization, based on the technology of complex sugar chemistry synthesis and quality analysis platform, we have designed and synthesized more than 20 new immune adjuvant molecules in six categories, including TLR3 (dsRNA), TLR4 (monophospholipid A), TLR7/8, TLR9 (oligonucleotides), saponins and NKT agonists, against the new adjuvant varieties approved by FDA.
CpG ODN
CpG ODN
Tumor Vaccine
Tumor Vaccine
AA100 — TLR4 adjuvant
AA200 — NKT excited
AA300 — Saponin adjuvant
AA400 — TLR7/8 adjuvant
AA100 — TLR4 adjuvant
AA200 — NKT excited
AA300 — Saponin adjuvant
AA400 — TLR7/8 adjuvant
AYK100(Immunoactivator+ICI)
AYK200(Tumor associated sugar antigen TACA)
AYK300(HPV vaccine)
AYK100(Immunoactivator+ICI)
AYK200(Tumor associated sugar antigen TACA)
AYK300(HPV vaccine)

11-30

On November 25-26, 2022, under the guidance of the Office of the Leading Group for the Development of the Shanghai Biomedical Industry, the 2022 China Biomedical Industry Innovation Conference, co-spo

09-23

On September 23, the group building base in Changxing Island was luxuriant with grass. The morning dew of grass and trees on the open lawn had already been cleared up by the dawn. The fresh air was fl

2022

08-03

On August 3, 2022, a delegation led by Mr. Chen of Chengdu Maikekang Biotechnology Co., Ltd. visited our company for inspection and guidance. Sui Qiang, General Manager of the company, and Ge Hibernat

2022

10-28

In order to eliminate fire hazards, improve the fire awareness of the whole staff, and enhance the emergency response and self-protection ability of employees in emergency situations, our company took

2022

07-01

On April 16, Chengdu Makkang Biotechnology Co., Ltd. (hereinafter referred to as Makkang Biotechnology) announced the completion of the pre-A round of financing of nearly 100 million yuan. This rou...

2022

07-01

On January 24, 2022, Chengdu Makikon Biotechnology Co., Ltd. and Shanghai Makikon Biotechnology Co., Ltd. received the Notification of Approval for Clinical Trials of Drugs issued by the State Drug...
NEWS
About Us                     Product Service       News                        WeChat
Ayk Biotechnology
An epidemic can be cured and the world can be helped. AECOM has the development opportunities of innovative companies and good prospects for personal career development. At present, the company is in a rapid development stage. Since its establishment, the research and development of adjuvant molecules have been among the top in the world.
TEL:0086-21-68403318
Add:Floor 5-6, Unit 2, Building 7, No. 160, Basheng Road, China (Shanghai)
         Pilot Free Trade Zone
Ayk WeChat